conferenceseries.com

Joint meet on 13th International Conference on PREDICTIVE, PREVENTIVE AND PERSONALIZED MEDICINE & MOLECULAR DIAGNOSTICS.

July 27, 2021 | Webinar

Introduction of cost-effectiveness and health economics evaluation in Precision Medicine

Hend Chaker
Tunisia

Precision medicine is an emerging approach for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle for each person. The advent of new technologies, the completion of Human Genome project and the collaborative efforts toward the translation of genomic discoveries into medical practice led to speed up the pace of genomic medicine implementation. Despite the advances of technologies and concentrated research on the field, widespread use of precision medicine, specifically genomic markers, in clinical care has been limited in practice to date. Lack of evidence on the cost-effectiveness and reimbursement related issues, have been cited as major barriers to translate these advances in clinical routine. Health economics frameworks and tools can elucidate the effects of legal, regulatory, and reimbursement policies to enhance the appropriate use of precision medicine. Cost-effectiveness analysis Guide public health priorities, guidelines, and reimbursement policies. We aim to introduce Cost-Effectiveness (CE) analysis in precision medicine, concepts and approaches of analysis, and to present examples of CE analysis, as the CE of HLAB*5701- screening test prior to Abacavir treatment (Pharmacogenomics), The CE analysis of Oncotype screening test (Breast-cancer, Oncology), and the CE analysis of Ivacaftor drug indicated in Cystic Fibrosis (monogenic disorders). In some applications related to precision medicine, the application of Health Economics is associated with complexity, regarding the limited ability to track use of precision medicine interventions and the complexity to capture the several outcomes associated with CE analysis of multiplex or panel testing that bring several outcomes in one-time use: genetic counselling, indication of target treatment or incidental findings, what invite more research in CE analysis applied to precision medicine.

Biography

Hend Chaker is from Institut Pasteur de Tunis. She did her Pharm. D and Clinical Biologist in Medical Genetics, M.Sc in Cytogenetics (Faculty of Medicine, University of Montreal, UDEM) in Tunisia, United Arab Emirates

hendchaker@gmail.com